Hospital
Saint Mary's Health Services
Saint Mary's Health Services was paid $91.92M by Medicaid between Jan 2018 and Dec 2024, across 615 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 23% of everything it billed.
33Billing provider infoSAINT MARY'S HEALTH SERVICES
GRAND RAPIDS, MI 49503
GRAND RAPIDS, MI 49503
33aNPI1639111057assigned 06/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$91.92M
24GClaims2,841,131
24DCodes billed615
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#11 of 86
Median peer was paid$21.55M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 349,253 | $10.44M | |
| 2019 | 348,717 | $9.47M | |
| 2020 | 319,538 | $9.93M | |
| 2021 | 458,443 | $15.77M | |
| 2022 | 479,833 | $16.11M | |
| 2023 | 504,801 | $16.89M | |
| 2024incomplete | 380,546 | $13.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 23% | 342,475 | 291,285 | $20.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 42,573 | 38,667 | $13.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 50,431 | 45,330 | $9.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.6% | 64,373 | 54,906 | $7.94M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.0% | 38,978 | 34,996 | $3.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 21,791 | 20,231 | $1.57M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.5% | 22,152 | 20,666 | $1.41M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 23,455 | 22,441 | $1.32M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.4% | 19,879 | 19,817 | $1.29M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 8,099 | 7,919 | $1.10M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 1.1% | 2,968 | 1,735 | $1.04M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.1% | 14,901 | 14,857 | $976K |
603 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 12,362 | $797K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 28,008 | $793K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,347 | $778K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,869 | $738K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 10,534 | $692K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 66,265 | $689K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,186 | $664K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 6,303 | $626K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 18,136 | $520K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 28,028 | $515K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 10,338 | $474K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,076 | $468K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 23,171 | $458K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 941 | $443K |
| 90677 | <1% | 3,511 | $437K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 30,214 | $433K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 30,193 | $433K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,156 | $430K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,919 | $421K |
| 59025 | Fetal non-stress test | <1% | 4,243 | $398K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,775 | $361K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 17,983 | $361K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,204 | $351K |
| 80061 | Lipid panel | <1% | 33,528 | $340K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,100 | $328K |
| 76801 | <1% | 5,400 | $318K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,474 | $317K |
| 80053 | Comprehensive metabolic panel | <1% | 114,739 | $305K |
| 20610 | <1% | 2,097 | $305K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,415 | $294K |
| 76830 | Ultrasound, transvaginal | <1% | 5,007 | $289K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 297 | $282K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,368 | $251K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 40,355 | $250K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,876 | $248K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,371 | $248K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,227 | $240K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 8,409 | $236K |
| 90686 | <1% | 27,862 | $229K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 105 | $227K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,940 | $226K |
| 87536 | <1% | 4,671 | $217K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 3,612 | $215K |
| 64615 | <1% | 1,626 | $212K | |
| 95811 | <1% | 479 | $203K | |
| 90651 | <1% | 5,920 | $201K | |
| G0378 | Hospital observation service, per hour | <1% | 5,893 | $194K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 104,733 | $178K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 11,768 | $173K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,058 | $168K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 5,860 | $168K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,636 | $166K |
| 90750 | <1% | 1,127 | $163K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,380 | $160K |
| 64400 | <1% | 1,067 | $159K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,844 | $153K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,327 | $152K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 372 | $149K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 35,614 | $141K |
| 93971 | <1% | 2,729 | $141K | |
| 64405 | <1% | 928 | $140K | |
| 99385 | <1% | 2,090 | $133K | |
| 10060 | <1% | 1,498 | $131K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,348 | $127K |
| 91320 | <1% | 1,177 | $126K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,803 | $124K |
| 86900 | <1% | 8,273 | $119K | |
| 97161 | <1% | 1,618 | $116K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,492 | $115K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,054 | $112K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,953 | $111K |
| 99381 | <1% | 1,704 | $107K | |
| 81513 | <1% | 1,769 | $105K | |
| 86360 | <1% | 3,754 | $97K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 118,740 | $95K |
| 70496 | <1% | 950 | $93K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,260 | $93K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,826 | $93K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,852 | $91K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 818 | $87K |
| 97162 | <1% | 1,124 | $85K | |
| 99383 | <1% | 1,274 | $84K | |
| 94726 | <1% | 1,213 | $84K | |
| 71250 | <1% | 1,611 | $80K | |
| 0002A | <1% | 2,277 | $79K | |
| 72141 | <1% | 608 | $76K | |
| 0001A | <1% | 2,497 | $74K | |
| 93976 | <1% | 1,287 | $71K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,043 | $71K |
| 76642 | <1% | 1,962 | $67K | |
| 85027 | <1% | 34,211 | $65K | |
| 76536 | <1% | 2,049 | $63K | |
| 86480 | <1% | 1,818 | $59K | |
| 86780 | <1% | 6,933 | $59K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,046 | $58K |
| 90620 | <1% | 1,799 | $56K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,059 | $54K |
| 82728 | <1% | 8,460 | $54K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,150 | $54K |
| 90480 | <1% | 1,639 | $53K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 445 | $53K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 3,263 | $50K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 20,517 | $50K |
| 87653 | <1% | 3,774 | $49K | |
| 17110 | <1% | 1,209 | $49K | |
| 90837 | Psychotherapy session, about an hour | <1% | 953 | $49K |
| 82607 | <1% | 7,123 | $48K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,871 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,761 | $47K |
| 90474 | <1% | 8,412 | $47K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,692 | $45K |
| 86803 | <1% | 6,984 | $45K | |
| 0124A | <1% | 1,474 | $43K | |
| 71271 | <1% | 747 | $42K | |
| 99384 | <1% | 633 | $42K | |
| 72100 | <1% | 3,059 | $42K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 986 | $42K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 304 | $42K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,037 | $40K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,157 | $39K |
| 84702 | <1% | 8,357 | $38K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 39 | $38K |
| 99382 | <1% | 573 | $37K | |
| 47562 | <1% | 12 | $35K | |
| 90746 | <1% | 489 | $33K | |
| 70491 | <1% | 290 | $33K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 164 | $33K |
| 73564 | <1% | 2,830 | $33K | |
| 83655 | <1% | 4,448 | $32K | |
| 70486 | <1% | 1,227 | $32K | |
| 80074 | <1% | 1,655 | $32K | |
| 95806 | <1% | 395 | $30K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,808 | $30K |
| 73030 | <1% | 3,698 | $30K | |
| 73562 | <1% | 2,342 | $30K | |
| 93017 | <1% | 1,119 | $29K | |
| 88342 | <1% | 1,176 | $29K | |
| 90732 | <1% | 415 | $29K | |
| 83970 | <1% | 1,648 | $28K | |
| 83550 | <1% | 6,859 | $28K | |
| 84439 | <1% | 7,896 | $28K | |
| 90670 | <1% | 12,083 | $28K | |
| 87340 | <1% | 7,288 | $28K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 70 | $27K |
| 96161 | <1% | 1,870 | $26K | |
| 97597 | <1% | 333 | $26K | |
| 0054A | <1% | 813 | $26K | |
| 87481 | <1% | 2,162 | $25K | |
| 99495 | <1% | 423 | $25K | |
| 76775 | <1% | 958 | $24K | |
| 99386 | <1% | 367 | $24K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,280 | $24K |
| 73630 | <1% | 4,329 | $23K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 396 | $23K |
| 83540 | <1% | 7,503 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 572 | $22K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,226 | $22K |
| 73502 | <1% | 2,464 | $22K | |
| 86592 | <1% | 8,661 | $22K | |
| 90678 | <1% | 74 | $22K | |
| 90734 | <1% | 4,913 | $21K | |
| 97165 | <1% | 759 | $21K | |
| 87186 | <1% | 7,714 | $21K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 341 | $20K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,944 | $20K |
| 0004A | <1% | 658 | $20K | |
| 73610 | <1% | 3,872 | $19K | |
| 83735 | <1% | 23,664 | $19K | |
| 81025 | <1% | 7,014 | $19K | |
| 90688 | <1% | 2,337 | $19K | |
| 97166 | <1% | 504 | $18K | |
| 84146 | <1% | 1,786 | $18K | |
| 83880 | <1% | 3,699 | $18K | |
| 84403 | <1% | 1,590 | $18K | |
| 99406 | <1% | 1,321 | $17K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 67 | $17K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,401 | $17K |
| 86762 | <1% | 4,136 | $17K | |
| 0012A | <1% | 502 | $17K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,589 | $16K |
| 73130 | <1% | 3,313 | $16K | |
| 87077 | <1% | 6,091 | $16K | |
| 82746 | <1% | 2,507 | $16K | |
| 90716 | <1% | 4,097 | $16K | |
| 87070 | <1% | 5,027 | $16K | |
| 92551 | <1% | 2,264 | $16K | |
| 87808 | <1% | 6,432 | $15K | |
| 93246 | <1% | 894 | $15K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,433 | $15K |
| 82043 | <1% | 5,794 | $15K | |
| 81001 | <1% | 45,611 | $15K | |
| 0071A | <1% | 508 | $15K | |
| 86850 | <1% | 8,138 | $14K | |
| 90656 | <1% | 1,680 | $14K | |
| 72110 | <1% | 460 | $14K | |
| 85610 | <1% | 13,589 | $14K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 39 | $14K |
| 74018 | <1% | 1,897 | $13K | |
| 94010 | <1% | 1,238 | $13K | |
| 0072A | <1% | 370 | $13K | |
| 96127 | <1% | 3,007 | $13K | |
| 90694 | <1% | 533 | $13K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 25 | $13K |
| 82570 | <1% | 6,012 | $13K | |
| 83001 | <1% | 1,290 | $12K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 43 | $12K |
| 0011A | <1% | 496 | $12K | |
| 96116 | <1% | 103 | $11K | |
| 97802 | <1% | 598 | $11K | |
| 84481 | <1% | 1,411 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,009 | $11K |
| 86787 | <1% | 2,404 | $11K | |
| 86593 | <1% | 3,183 | $11K | |
| 73110 | <1% | 2,060 | $11K | |
| 83516 | <1% | 1,235 | $10K | |
| 82670 | <1% | 649 | $10K | |
| 86235 | <1% | 242 | $10K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 57 | $10K |
| 86706 | <1% | 1,984 | $10K | |
| 93970 | <1% | 97 | $10K | |
| 0052A | <1% | 266 | $9K | |
| 86140 | <1% | 5,496 | $9K | |
| 72040 | <1% | 679 | $9K | |
| 70320 | <1% | 86 | $9K | |
| 91200 | <1% | 168 | $8K | |
| 87205 | <1% | 9,603 | $8K | |
| 82962 | <1% | 8,158 | $8K | |
| 99493 | <1% | 249 | $8K | |
| 11982 | <1% | 92 | $8K | |
| 87210 | <1% | 5,835 | $8K | |
| 82784 | <1% | 1,259 | $8K | |
| 0051A | <1% | 240 | $8K | |
| 80076 | <1% | 2,188 | $8K | |
| 73140 | <1% | 895 | $8K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 150 | $8K |
| 80305 | <1% | 8,677 | $7K | |
| 82950 | <1% | 2,580 | $7K | |
| 76870 | <1% | 376 | $7K | |
| 92083 | <1% | 1,231 | $7K | |
| 96367 | <1% | 169 | $7K | |
| 80069 | <1% | 1,896 | $7K | |
| 85018 | <1% | 6,122 | $7K | |
| 74021 | <1% | 730 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,772 | $7K |
| 90682 | <1% | 113 | $7K | |
| 83002 | <1% | 690 | $6K | |
| 86364 | <1% | 616 | $6K | |
| 84703 | <1% | 25,750 | $6K | |
| 86769 | <1% | 362 | $6K | |
| 87088 | <1% | 2,756 | $6K | |
| 95700 | <1% | 68 | $6K | |
| 64483 | <1% | 14 | $6K | |
| 86039 | <1% | 1,195 | $6K | |
| 43235 | <1% | 27 | $6K | |
| 85007 | <1% | 5,168 | $6K | |
| 82105 | <1% | 678 | $6K | |
| 81002 | <1% | 4,667 | $6K | |
| 88307 | <1% | 223 | $6K | |
| 80164 | <1% | 1,509 | $6K | |
| 82951 | <1% | 745 | $6K | |
| 85652 | <1% | 6,006 | $6K | |
| 0081A | <1% | 149 | $5K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 446 | $5K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $5K |
| 81003 | <1% | 12,032 | $5K | |
| 86258 | <1% | 404 | $5K | |
| 82947 | <1% | 206 | $5K | |
| 86704 | <1% | 975 | $5K | |
| 93350 | <1% | 30 | $5K | |
| 92133 | <1% | 1,986 | $5K | |
| 95713 | <1% | 24 | $5K | |
| 11981 | <1% | 136 | $5K | |
| 93351 | <1% | 17 | $5K | |
| 87147 | <1% | 3,054 | $5K | |
| 83690 | <1% | 19,350 | $5K | |
| 87902 | <1% | 41 | $4K | |
| 82248 | <1% | 1,751 | $4K | |
| 77080 | <1% | 77 | $4K | |
| 72072 | <1% | 313 | $4K | |
| 73080 | <1% | 995 | $4K | |
| 0154A | <1% | 120 | $4K | |
| 57454 | <1% | 26 | $4K | |
| 84425 | <1% | 362 | $4K | |
| 86038 | <1% | 665 | $4K | |
| 69209 | <1% | 763 | $4K | |
| 20553 | <1% | 32 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 219 | $4K |
| 74183 | <1% | 28 | $4K | |
| 87899 | <1% | 378 | $4K | |
| 95909 | <1% | 25 | $4K | |
| 85730 | <1% | 5,344 | $4K | |
| 84550 | <1% | 2,025 | $4K | |
| 84156 | <1% | 2,941 | $4K | |
| 80055 | <1% | 112 | $4K | |
| 82550 | <1% | 2,540 | $4K | |
| 95913 | <1% | 12 | $4K | |
| 70498 | <1% | 837 | $4K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 12 | $3K |
| 83615 | <1% | 1,629 | $3K | |
| 84100 | <1% | 3,661 | $3K | |
| 82140 | <1% | 1,086 | $3K | |
| 73560 | <1% | 411 | $3K | |
| 86901 | <1% | 8,659 | $3K | |
| 87081 | <1% | 3,070 | $3K | |
| 80197 | <1% | 546 | $3K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 45 | $3K |
| 76882 | <1% | 85 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,751 | $3K |
| 0003A | <1% | 105 | $3K | |
| 88341 | <1% | 105 | $3K | |
| 87529 | <1% | 138 | $3K | |
| 10005 | <1% | 13 | $3K | |
| 74019 | <1% | 372 | $3K | |
| 73590 | <1% | 870 | $3K | |
| 94060 | <1% | 27 | $3K | |
| 95819 | <1% | 29 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 107 | $3K |
| 86431 | <1% | 1,116 | $3K | |
| 0082A | <1% | 79 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 17 | $3K |
| 86580 | <1% | 374 | $3K | |
| 82044 | <1% | 1,293 | $3K | |
| 11750 | <1% | 16 | $3K | |
| 71101 | <1% | 719 | $3K | |
| 80159 | <1% | 259 | $3K | |
| 96415 | <1% | 46 | $3K | |
| 88142 | <1% | 317 | $3K | |
| 78320 | <1% | 15 | $3K | |
| 86696 | <1% | 292 | $3K | |
| 84484 | <1% | 22,658 | $2K | |
| 58100 | <1% | 24 | $2K | |
| 90662 | <1% | 265 | $2K | |
| 96118 | <1% | 27 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 112 | $2K |
| 87220 | <1% | 4,568 | $2K | |
| 87641 | <1% | 180 | $2K | |
| 80081 | <1% | 93 | $2K | |
| 99484 | <1% | 124 | $2K | |
| 95812 | <1% | 12 | $2K | |
| 88304 | <1% | 842 | $2K | |
| 84153 | <1% | 284 | $2K | |
| 80178 | <1% | 869 | $2K | |
| 58301 | <1% | 15 | $2K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 12 | $2K |
| 74178 | <1% | 12 | $2K | |
| 83020 | <1% | 450 | $2K | |
| 86695 | <1% | 293 | $2K | |
| 90744 | <1% | 4,388 | $2K | |
| 87040 | <1% | 2,761 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,576 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 451 | $2K |
| 86708 | <1% | 279 | $2K | |
| 82247 | <1% | 584 | $2K | |
| 87338 | <1% | 222 | $1K | |
| 87901 | <1% | 24 | $1K | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 18 | $1K |
| 99492 | <1% | 44 | $1K | |
| 82952 | <1% | 653 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 131 | $1K |
| 86923 | <1% | 64 | $1K | |
| 85379 | <1% | 4,664 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 51 | $1K |
| 73700 | <1% | 26 | $1K | |
| 0074A | <1% | 56 | $1K | |
| 85045 | <1% | 698 | $1K | |
| 76770 | <1% | 14 | $1K | |
| 84590 | <1% | 160 | $1K | |
| 90653 | <1% | 90 | $1K | |
| 87400 | <1% | 1,000 | $1K | |
| 82533 | <1% | 118 | $1K | |
| 86225 | <1% | 154 | $972.16 | |
| 83605 | <1% | 11,709 | $969.69 | |
| 96132 | <1% | 14 | $949.39 | |
| 86200 | <1% | 161 | $947.21 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 38 | $930.23 |
| 12001 | <1% | 1,240 | $915.09 | |
| 87045 | <1% | 249 | $911.67 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 48 | $860.91 |
| 86376 | <1% | 111 | $839.63 | |
| 86003 | <1% | 25 | $793.23 | |
| 11721 | <1% | 59 | $746.65 | |
| 82805 | <1% | 1,417 | $734.50 | |
| 87900 | <1% | 24 | $733.09 | |
| 85660 | <1% | 422 | $725.55 | |
| 87517 | <1% | 50 | $689.08 | |
| 93298 | <1% | 40 | $676.71 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 257 | $652.69 |
| 58300 | <1% | 40 | $648.94 | |
| 76000 | <1% | 132 | $594.62 | |
| 82565 | <1% | 927 | $592.45 | |
| 73090 | <1% | 204 | $570.00 | |
| 0031A | <1% | 19 | $543.55 | |
| 87563 | <1% | 31 | $531.11 | |
| 86800 | <1% | 61 | $483.15 | |
| 87449 | <1% | 84 | $462.22 | |
| 82150 | <1% | 140 | $387.43 | |
| 0053A | <1% | 13 | $380.55 | |
| 86682 | <1% | 62 | $364.62 | |
| 88173 | <1% | 15 | $356.73 | |
| 87806 | <1% | 1,341 | $350.11 | |
| 87015 | <1% | 123 | $348.75 | |
| 87046 | <1% | 98 | $346.64 | |
| 87906 | <1% | 12 | $333.67 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,232 | $333.42 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 19 | $331.90 |
| 90756 | <1% | 12 | $306.90 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 235 | $305.60 |
| 82274 | <1% | 25 | $260.91 | |
| 92060 | <1% | 546 | $256.03 | |
| 72050 | <1% | 12 | $245.82 | |
| 82652 | <1% | 16 | $242.44 | |
| 87430 | <1% | 3,054 | $235.39 | |
| 82330 | <1% | 32 | $235.38 | |
| 87075 | <1% | 104 | $234.76 | |
| 82010 | <1% | 1,167 | $233.55 | |
| 87101 | <1% | 88 | $223.71 | |
| 84144 | <1% | 22 | $222.81 | |
| 91319 | <1% | 159 | $217.96 | |
| 69210 | <1% | 77 | $216.12 | |
| 84466 | <1% | 42 | $209.79 | |
| 82955 | <1% | 44 | $206.23 | |
| 12011 | <1% | 438 | $198.90 | |
| 84480 | <1% | 27 | $186.82 | |
| 86308 | <1% | 289 | $174.15 | |
| 93299 | <1% | 13 | $171.56 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 299 | $170.98 |
| 82627 | <1% | 12 | $168.22 | |
| 91318 | <1% | 146 | $162.82 | |
| 87807 | <1% | 583 | $160.89 | |
| 83993 | <1% | 13 | $159.21 | |
| 87106 | <1% | 38 | $158.44 | |
| 90698 | <1% | 6,981 | $158.08 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 6,827 | $156.00 |
| 84436 | <1% | 52 | $155.56 | |
| 72220 | <1% | 14 | $146.54 | |
| 93270 | <1% | 13 | $135.24 | |
| 86920 | <1% | 27 | $131.88 | |
| 95886 | <1% | 1,532 | $129.52 | |
| 86703 | <1% | 494 | $123.48 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 232 | $101.11 |
| 73000 | <1% | 14 | $101.09 | |
| 84165 | <1% | 27 | $96.99 | |
| 88172 | <1% | 17 | $79.59 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,743 | $77.11 |
| 84402 | <1% | 12 | $71.75 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 25,263 | $71.26 |
| 87324 | <1% | 12 | $69.88 | |
| 72170 | <1% | 38 | $64.84 | |
| 93922 | <1% | 53 | $64.79 | |
| 76380 | <1% | 68 | $63.24 | |
| 86665 | <1% | 23 | $61.32 | |
| 93325 | <1% | 561 | $60.01 | |
| 96376 | <1% | 7,197 | $59.44 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 755 | $58.18 |
| 90715 | <1% | 11,530 | $57.60 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 53 | $52.20 |
| 73552 | <1% | 29 | $49.45 | |
| 81000 | <1% | 26 | $46.02 | |
| 97116 | <1% | 31 | $45.63 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,942 | $45.12 |
| 93356 | <1% | 1,067 | $43.56 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29,714 | $41.85 |
| 87581 | <1% | 235 | $40.56 | |
| 87486 | <1% | 235 | $40.55 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 19 | $38.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 27,891 | $34.97 |
| 87209 | <1% | 26 | $29.74 | |
| 85004 | <1% | 16 | $29.12 | |
| 87102 | <1% | 15 | $23.60 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,272 | $19.09 |
| 84460 | <1% | 13 | $17.60 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,374 | $17.44 |
| 87177 | <1% | 26 | $14.87 | |
| 99152 | <1% | 172 | $13.86 | |
| 96138 | <1% | 67 | $12.91 | |
| 94760 | <1% | 226 | $12.50 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,511 | $12.45 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,810 | $11.30 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 5,245 | $11.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,939 | $10.26 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,935 | $8.50 |
| 83520 | <1% | 1,912 | $6.00 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,233 | $4.38 |
| A9270 | Non-covered item or service | <1% | 3,749 | $3.59 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,637 | $2.99 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 11,055 | $2.93 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,684 | $2.71 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 42 | $2.19 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,480 | $2.04 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,036 | $1.87 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 89 | $1.64 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 966 | $1.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,256 | $1.00 |
| 36416 | <1% | 1,827 | $0.92 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 102 | $0.50 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 381 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 256 | $0.00 |
| 90648 | 0% | 5,998 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 523 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 2,705 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,984 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 989 | $0.00 |
| 90700 | 0% | 2,774 | $0.00 | |
| 90707 | 0% | 4,004 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 65 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,490 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 449 | $0.00 |
| 90681 | 0% | 2,720 | $0.00 | |
| 90633 | 0% | 7,536 | $0.00 | |
| 94729 | 0% | 1,148 | $0.00 | |
| 90710 | 0% | 3,208 | $0.00 | |
| 90685 | 0% | 990 | $0.00 | |
| 91300 | 0% | 383 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 1,049 | $0.00 |
| 77002 | 0% | 221 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 155 | $0.00 |
| J1071 | Injection, testosterone cypionate, 1 mg | 0% | 19 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 40 | $0.00 |
| A4315 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way, all silicone | 0% | 24 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 330 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 1,522 | $0.00 |
| 76376 | 0% | 708 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 57 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 251 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 66 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 13 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 124 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 71 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 17 | $0.00 |
| 29125 | 0% | 25 | $0.00 | |
| 76937 | 0% | 93 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 77 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 166 | $0.00 |
| 90713 | 0% | 64 | $0.00 | |
| 87660 | 0% | 12 | $0.00 | |
| 76942 | 0% | 24 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 13 | $0.00 |
| 90671 | 0% | 91 | $0.00 | |
| 99173 | 0% | 92 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 19 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 12 | $0.00 |
| 0502F | 0% | 39 | $0.00 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 21 | $0.00 |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 13 | $0.00 |
| 64447 | 0% | 12 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 191 | $0.00 |
| 90696 | 0% | 3,242 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 882 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 1,785 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,309 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,650 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 28 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 249 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 4,440 | $0.00 |
| 90680 | 0% | 6,385 | $0.00 | |
| 90647 | 0% | 952 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 3,527 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 522 | $0.00 |
| 90723 | 0% | 5,148 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 777 | $0.00 |
| 73660 | 0% | 13 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 6,652 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 522 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 1,230 | $0.00 |
| 12002 | 0% | 163 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 3,565 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 321 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 9,867 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 404 | $0.00 |
| C1769 | Guide wire | 0% | 1,210 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 185 | $0.00 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 1,868 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 323 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| 93320 | 0% | 184 | $0.00 | |
| 95885 | 0% | 55 | $0.00 | |
| 99494 | 0% | 113 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 306 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 70 | $0.00 |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | 0% | 30 | $0.00 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 412 | $0.00 |
| 90632 | 0% | 78 | $0.00 | |
| 96139 | 0% | 67 | $0.00 | |
| 0352U | 0% | 839 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 52 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 25 | $0.00 |
| 90619 | 0% | 52 | $0.00 | |
| 87480 | 0% | 12 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 15 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 30 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 43 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 14 | $0.00 |
| 80320 | 0% | 33 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 51 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 87510 | 0% | 12 | $0.00 | |
| 64415 | 0% | 12 | $0.00 | |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | 0% | 28 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| 90381 | 0% | 12 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 12 | $0.00 |
| 84270 | 0% | 13 | $0.00 | |
| 73060 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIERSACK, MATTHEW (PRESIDENT)